Day 2 Friday

Board	Abstract			Title
number	number	Presentii	ng Author	Titte
Hamber	Hamber	110301111	TIS MULTION	Potentially significant drug-drug interactions:
				A Real-world retrospective study on patients
				receiving psychotropic medications at
1	11	Rania	AbuKuhail	Mental Health Services
				Improving vitamin D prescribing and level
				monitoring for psychiatric patients at Mental
2	12	Rania	AbuKuhail	Health Services in Qatar
				Deprescribing Medications in Geriatric Care
				to Enhance Safety and Quality of Life: A
3	13	Dr. Dalal	AL-Harbi	Vision 2030 Aligned Initiative
				Retrospective Comparative Analysis of FDC
				versus SDC for Helicobacter pylori
4	17	Bhagya	Sree	Eradication
				Evaluation of psychological disorders in
				hemodialysis patients and impact of
				Pharmacist's educational intervention on
5	21	Salamat	Ali	health related quality of life
				The Effectiveness of Interactive Dashboards
				to Enhance the Quality of Antibiotics
6	27	Salamat	Ali	Prescribing in Primary Healthcare
				COMMUNITY PHARMACISTS' PERCEPTION
				AND ATTITUDE ABOUT PATIENT
_	20	Cilma	Casilwanaa	COUNSELING AND ONGOING PHARMACY
7	30	Silpa	Sasikumar	EDUCATION PROGRAMS IN QATAR
				Medication Use Evaluation of Semaglutide at
8	37	Zeana	Alkudsi	AlWakra Hospital
0	37	Zeana	Aikuusi	Development of an innovative clinical
				pharmacy service in a urology surgical
9	47	Lina	Nasrallah	unit: A new initiative from Qatar
9	4/	LIIId	เงสอเสแสแ	unit. A new initiative nom Qatai
				Analysis of clinical pharmacists'
10	48	Zahra	Noureddine	interventions in a rehabilitation setting
10	70	Zumu	Hoursdame	
				Clinical Outcomes of Implementing
11	49	Zeana	Alkudsi	Diabetic Ketoacidosis PowerPlan
				Role of the PHCC pharmacist in
12	50	Aisha	Rayashi	utilization of near expiry medications

				Safer Care through intensive medications
13	60	Nawaf	Almudhi	reconciliations (IMR)
				Quantitative and qualitative
				assessments of medication
				reconciliation module for hospital
				pharmacists in the United Arab
14	62	Alaa	Farajallah	Emirates: lessons learned
				Evaluation of drug-related problems by
				clinical pharmacists in Intensive Care
15	66	Amna	Othman	Unit: A Systemic Review
				Clinical audit to limit protease inhibitor-
				based regimen use among adult living
				with human immunodeficiency virus
16	69	Shiema	Abdullah	(HIV)
	-			Efficacy and Safety of Iron Treatment
				Strategies in Athletes with Iron Deficiency
17	70	Dana	Elkhalifa	and Iron Deficiency Anemia in Qatar
				, ,
				Pharmacists' perspectives on depression
18	73	Ala	shalash	care: A scoping review
				Improving Compliance of the Narcotic
				and Controlled Medications Maintenance
		Salma Abdel		Checklist in the Heart Hospital-A Quality
19	75	Hameid	Ismail	Improvement Project
				Improve Emergency Cart Medications
				Management to Error Proof in the Heart
		Salma Abdel		Hospital-A Quality Improvement Project
20	76	Hameid	Ismail	
				Improving Reporting of Adverse Drug
		Salma Abdel		Reactions by the Operational
21	77	Hameid	Ismail	Pharmacists in the Heart Hospital
				Artificial Intelligence (AI) in Pharmacy: a
22	81	sajna	jamsheed	scoping review
	01	Sajiid	janisneeu	Reducing NSAID Prescriptions in Patients
				Receiving ACE Inhibitors/ARBs and
				Diuretics: A Quality Improvement
23	88	Houda	Dhiab	Initiative
23	00	Houda	חוומט	inidative
				Adverse Reactions to Intravenous
24	89	Yehia	Elkhawly	Carboxymaltose: A Closer Look
			-	
				Optimizing Medication Reconciliation
25	90	Yehia	Elkhawly	Practices in the Obstetrics and

				Gynecology Department: A Quality
				Improvement Initiative
				Prevalence, Causative Microorganisms,
				and Antibiotic Sensitivity of UTIs in
				Pregnant Women: A Retrospective Study
26	91	Naji	Abdallah	at AWH
				Improving Influenza Vaccination Rates in
				Pregnancy: A Clinical Pharmacist-Led
27	92	Naji	Abdallah	Pilot Study
				Efficacy and Safety of Dinoprostone
				Formulations in Cervical Ripening and
28	93	Naji	Abdallah	Labor Induction: A Comparative Study
				Effectiveness of Carbetocin in Preventing
				Post-Partum Hemorrhage in High-Risk
29	94	Naji	Abdallah	Women: A Prospective Clinical Audit
				Exploring Viewpoints of Health Care
				Professionals on Patients Adherence to
		Abdel		Oral Anti Coagulants in Eastern Saudi
30	99	Rahman	Medani	Arabia
				Patients' and primary carers' views on
				clozapine treatment for schizophrenia: a
31	109	YASSIN	ELTORKI	cross-sectional study in Qatar
				Prescription pattern of ocular
				hypotensive therapy and knowledge of
32	124	Amal	Aldarwesh	patients with advanced glaucoma
				The Association between Plasma
				Sestrin2 Levels and the Risk of Acute
33	126	Loulia	Bader	Ischemic Stroke: A Case Cohort Study
				Safety of high-dose versus standard-dose
				influenza vaccination on long term
_				residents admitted in Rumailah hospital:
34	129	Afraa	Abbas	a retrospective study
				NephroXpert: An Intelligent Platform for
35	156	Razan	Binkhunaysir	Personalized estimation of glomerular filtration rate (GFR)
33	130	ιταζατι	וואווומומאווום	Budget Impact Analysis of Subcutaneous
				versus Intravenous Trastuzumab for HER2-
36	202	Farah	Radaideh	Positive Breast Cancer in Jordan
				Efficacy and safety of adding ribavirin to
				direct-acting antivirals (DAAs) in re-treating
				non-genotype1 hepatitis C- a systematic
37	7	Shahd	Hamran	review and meta-analysis.

Depression Levels Among Lebanese	Psychological Impact of Acne on
Psychological Impact of Acne on	
43 110 Emelith Cerbito Lapatinib Psychological Impact of Acne on	43 110 Emelith Cerbito Lapatinib
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
Reporting System (FAERS) Data for Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Therapeutic Inertia Quantification in 42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Therapeutic Inertia Quantification in 42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Therapeutic Inertia Quantification in 42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	Therapeutic Inertia Quantification in 42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Qatar: A Qualitative Study Using Semi- Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It' A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	41 72 Jawaher Abdullah Structured Interviews Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Therapeutic Inertia Quantification in 42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Therapeutic Inertia Quantification in 42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Therapeutic Inertia Quantification in Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Therapeutic Inertia Quantification in 42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
43 110 Emelith Cerbito Lapatinib	
43 110 Emelith Cerbito Lapatinib	
43 110 Emelith Cerbito Lapatinib	
	43 110 Emelith Cerbito Lapatinib
	43 110 Emettin Cerbito Lapatinib
Psychological Impact of Acne on	
Psychological impact of Acrie on	Dough alorical Impact of Aspa on
	Psychological Impact of Acne on
December 1 - 1 - Acceptable and a second sec	
Depression Levels Among Lebanese	
	Depression Levels Among Lebanese
44 111 Mohammad Assi Adolescents: A Cross-Sectional Study	Depression Levels Among Lebanese
,	
Dihydropyrimidine dehydrogenase	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study
	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study
deficiency (DPYD) genotyning-guided	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase
	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase
fluoropyrimidine-based adjuvant	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study
	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided
	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase
ahamatharani far braact cancer An	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant
chemotherapy for breast cancer. An	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided
	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An
chemotherapy for breast cancer. An 45	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An
45 117 Dina Abushanab economic evaluation	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation
45 117 Dina Abushanab economic evaluation	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity
45 117 Dina Abushanab economic evaluation	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk 46 119 Dina Abushanab Factors Control in Type 2 Diabetes
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes Association of plasma levels of Sestring	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes Association of plasma levels of Sestring	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function indices in healthy and diabetic subject	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk 46 119 Dina Abushanab Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function indices in healthy and diabetic subjects
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function indices in healthy and diabetic subject	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function indices in healthy and diabetic subjects
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function indices in healthy and diabetic subjects
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl 46 119 Dina Abushanab Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function indices in healthy and diabetic subject	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An 45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function indices in healthy and diabetic subjects
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin. with adiposity and metabolic function indices in healthy and diabetic subject 47 122 Muhammad A Zahid from Qatar Biobank	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function indices in healthy and diabetic subjects from Qatar Biobank
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function indices in healthy and diabetic subject 47 122 Muhammad A Zahid from Qatar Biobank Application of solid dispersion in conjunction	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function indices in healthy and diabetic subjects from Qatar Biobank Application of solid dispersion in conjunction
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function indices in healthy and diabetic subject from Qatar Biobank Application of solid dispersion in conjunction	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function indices in healthy and diabetic subjects from Qatar Biobank Application of solid dispersion in conjunction
45 117 Dina Abushanab economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risl Factors Control in Type 2 Diabetes Association of plasma levels of Sestring with adiposity and metabolic function indices in healthy and diabetic subject from Qatar Biobank Application of solid dispersion in conjunction	44 111 Mohammad Assi Adolescents: A Cross-Sectional Study Dihydropyrimidine dehydrogenase deficiency (DPYD) genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. An economic evaluation Unraveling the Future Productivity Burden of Cardiovascular Disease in Qatar: Investigating the Modifiable Risk Factors Control in Type 2 Diabetes Association of plasma levels of Sestrin2 with adiposity and metabolic function indices in healthy and diabetic subjects from Qatar Biobank Application of solid dispersion in conjunctio with 3D printing for personalized medicine
Psychological Impact of Acne on	
Psychological Impact of Acne on	
Psychological impact of Ache on	De de la Carthanna de Characana
Psychological impact of Acrie on	Dough alorical Impact of Aspa on
Psychological impact of Ache on	Doughological Impact of Appa on
Psychological impact of Ache on	Doughological Impact of Appa on
Psychological impact of Ache on	Developed with a lower of Anna and
Psychological Impact of Acne on	
	40 110 Emedia October
	43 110 Emelith Cerbito Lapauliib
	43 110 Emelith Cerbito Lapatinib
	43 110 Emelith Cerbito Lapatinib
43 110 Emelith Cerbito Lapatinib	
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
Reporting System (FAERS) Data for Lapatinib	Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for 43 110 Emelith Cerbito Lapatinib	A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for
42 105 Ikram Zoukh Diabetes Care: How Do We Measure It A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Ever Reporting System (FAERS) Data for Lapatinib	42 105 Ikram Zoukh Diabetes Care: How Do We Measure It? A Comprehensive Real-world Safety Profile Analysis of the FDA Adverse Even Reporting System (FAERS) Data for

				AMLODIPINE ORALLY DISSOLVING
				FILMS FOR CHILDREN: ENHANCED
49	56	Renuka	Basineni	SOLUBILITY AND DRUG RELEASE
				Efficient Labeling of PLGA Nanocarriers
				with PLA-Capped Ultrasmall Gold
50	58	Andrew	Ebenazer	Nanoprobes
				Anthracyclines-Induced Vascular
				Endothelial Dysfunction in Cancer
				Patients and Survivors using Brachial
				flow-mediated dilation (FMD) tool: A
51	64	Lana	Kattan	Systematic Review and Meta-Analysis
				Analytical validation of Dried Blood Spot
				sampling for Lutetium-177 dosimetry in
				prostate cancer: assessing hematocrit
52	79	Ilham	Bumanjal	and punch location effects.
				Silver Nanoparticle Pharmaceutical
				Hydrogels: Large-Scale Manufacturing,
50	00	A la i	l loos simi	Antimicrobial Efficacy, and Falcon
53	36	Arshiya	Husaini	Pododermatitis Case Study
				Investigating Strategies to Enhance Aqueous Solubility of Ketamine HCl for Intranasal
54	38	sourour	idoudi	Delivery
04	- 00	3001001	laoaai	Boosting Intranasal Ketamine Delivery:
				Innovative Formulations with DDM and
55	39	sourour	idoudi	Poloxamer Thermoresponsive Gel
				Impact of Obesity on Rivaroxaban
				Pharmacokinetics: A Systematic Review
56	44	Majdoleen	Alalawneh	•
				Molecular and biopharmaceutical
				characterisation of Ciprofloxacin ester
				salts for enhancing solubility and
57	51	Tarnim	Hafez	permeability
				Population pharmacokinetics model of
	404	Maka	A.I. N.AI	vancomycin among critically ill obese
58	101	Mohammed	Al-Muhur	adult Saudi populations
				Investigating the impact of involving students in constructing a real-world case study as a
				learning strategy to deepen their learning and
59	28	Anwar.M	Aljurfi	understanding: A Pilot prospective study
			,	Curriculum, competency development, and
				assessment methods of MSc and PhD
60	33	Ola	Hussein	pharmacy programs: a scoping review
				Doubling to income and the latest the second
	40	0-1	D! !	Best timing to improve medical students'
61	46	Salma	Baddou	attitudes towards physician-pharmacist

				collaboration by using an educational
				podcast
				Empowering early career pharmacists:
				unleashing non-clinical competencies
62	59	Tarik	Al-Diery	through foundation pharmacy residency
				A Reflection on a Transforming
				Experience with Value Improvement
		Salma Abdel		Program and a Call for National and
63	78	Hameid	Ismail	International Pharmacy Experience
				Hospital pharmacists' perspectives on
				integrating artificial intelligence (AI) into
				continuing professional development
64	80	sundus	aldakhil	(CPD): A Qualitative study
				A 12-year Scientometric Analysis of
				Research Productivity among Clinical
				Pharmacy and Practice Faculty Members
65	103	Ahmed	Awaisu	at Qatar University
				Adapting Team-Based Learning for
				clinical skills training of undergraduate
66	154	Ahsan	Sethi	medical students
				Perceptions of Pharmacy Students and
				Clinical Preceptors on Feedback during
67	170	Dania	ALKHIYAMI	Experiential Learning
				Evaluation of an Integrated In Silico Modeling
				Module in an Undergraduate Pharmacy
				Technology Program: Enhancing
				Competency in Biopharmaceutics and
68	185	Marah	Yousif	Pharmacokinetics